Shear-thinning self-healing networks

US11517538B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11517538-B2
Application numberUS-202117342368-A
CountryUS
Kind codeB2
Filing dateJun 8, 2021
Priority dateSep 24, 2014
Publication dateDec 6, 2022
Grant dateDec 6, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.

First claim

Opening claim text (preview).

We claim: 1. A method for treating a patient in need thereof, the method comprising administering to the patient a shear-thinning injectable hydrogel comprising: one or more therapeutic, prophylactic or diagnostic agents, one or more biocompatible gel-forming polymers selected from the group consisting of polysaccharides and proteins, optionally modified with one or more ester, carbonate, amide, carbamate, urea, ether or amine-linked capping groups, and nanoparticles having a diameter between 10 nm and 1000 nm formed of one or more biocompatible amphiphilic polymers comprising one or more hydrophobic polymers selected from the group consisting of polyanhydrides, poly(ortho)esters, polyesters, polyurethanes, and copolymers comprising the monomers of these polymers and one or more hydrophilic polymers selected from the group consisting of polysaccharides, proteins polyamino acids, polyalkylene oxides, optionally including an electrostatic charge enhancing agent, wherein the nanoparticles are non-covalently bound to multiple biocompatible gel-forming polymers to form the shear-thinning injectable hydrogel comprising between about 1 and 15 wt % nanoparticles in the shear-thinning injectable hydrogel, the hydrogel comprising one or more therapeutic, prophylactic or diagnostic agents encapsulated within the nanoparticles, associated with the surface of the particles and/or dispersed through the hydrogel, wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive, is greater than the sum of the dynamic shear viscosity of a suspension of the nanoparticles and a solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 2. The method of claim 1 , wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 2 and 100,000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 3. The method of claim 2 , wherein the dynamic shear viscosity of the hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 2 and 1,000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 4. The method of claim 3 , wherein the dynamic shear viscosity of the hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 10 and 1000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 5. The method of claim 4 , wherein the dynamic shear viscosity of the shear-thinning injectable hydrogel at a shear rate within the range between 0.1 s −1 and 100 s −1 is a multiplicative factor of between 100 and 1000 times, inclusive, greater than the sum of the dynamic shear viscosity of the suspension of nanoparticles and the solution of the one or more biocompatible gel-forming polymers at the shear rate within the range between 0.1 s −1 and 100 s −1 , inclusive. 6. The method of claim 1 , wherein at least one of the one or more biocompatible gel-forming polymers is a polysaccharide selected from the group consisting of celluloses, hyaluronic acids, dextrans, xanthans and combinations thereof. 7. The method of claim 6 , wherein the polysaccharide is a cellulose or a modified cellulose. 8. The method of claim 7 , wherein the cellulose is hydroxypropyl methylcellulose or carboxymethyl cellulose. 9. The method of claim 1 , wherein the one or more biocompatible gel-forming polymers are modified with one or more ester, carbonate, amide, carbamate, urea, ether or amine-linked capping groups. 10. The method of claim 9 , wherein the one or more capping groups are selected from the group consisting of C 1 -C 20 alkyl groups, C 3 -C 18 cycloalkyl groups, and C 6 -C 18 aryl, wherein any of the C 1 -C 20 alkyl groups, C 3 -C 18 cycloalkyl groups, and C 6 -C 18 aryl groups may be unsubstituted or substituted one or more times. 11. The method of claim 1 , wherein the one or more biocompatible gel-forming polymers are at a concentration of between about 0.1 wt. % and about 10 wt. % prior to mixing with the nanoparticles. 12. The method of claim 1 , wherein the one or more biocompatible amphiphilic polymers comprise one or more hydrophobic polymers selected from the group consisting of polymers of lactic acid and glycolic acid, poly(butic acid), poly(valeric acid), poly(caprolactone), poly(hydroxybutyrate), poly(ethylene-co-maleic anhydride), poly(ethylene maleic anhydride-co-L-dopamine), poly(ethylene maleic anhydride-co-phenylalanine), poly(ethylene maleic anhydride-co-tyrosine), poly(butadiene-co-maleic anhydride), poly(butadiene maleic anhydride-co-L-dopamine), poly(butadiene maleic anhydride-co-phenylalanine), poly(butadiene maleic anhydride-co-tyrosine), and copolymers comprising the monomers of these polymers. 13. The method of claim 1 , wherein the nanoparticles comprise a core-shell nanoparticle. 14. The method of claim 1 , wherein the one or more biocompatible amphiphilic polymers are a poly(alkylene oxide)-block-(polyester). 15. The method of claim 1 , wherein the one or more biocompatible amphiphilic polymers are a poly(ethylene glycol)-block-poly(lactic acid). 16. The method of claim 1 , wherein the one or more biocompatible gel-forming polymers are charged at physiological conditions. 17. The method of claim 1 , wherein the one or more biocompatible gel-forming polymers are selected from the group consisting of hyaluronic acid, xanthan, and guar. 18. The method of claim 17 , wherein at least one of the one or more biocompatible gel-forming polymers is hyaluronic acid. 19. The method of claim 1 , wherein the one or more biocompatible gel-forming polymers are selected from the group consisting of aminopolysaccharides and positively charged proteins. 20. The method of claim 1 , further comprising an ionic surfactant. 21. The method of claim 20 , wherein the ionic surfactant is a cationic surfactant when the one or more biocompatible gel-forming polymers are negatively charged at physiological conditions. 22. The method of claim 21 , wherein the cationic surfactant is selected from the group consisting of cetyltrimethylammonium bromide, cetyltrimethylammonium iodide, cetyltrimethylammonium fluoride, and cetyltrimethylammonium chloride. 23. The method of claim 22 , wherein the cationic surfactant is cetyltrimethylammonium bromide. 24. The method of claim 20 , wherein the ionic surfactant is an anionic surfactant when the one or more biocompatible gel-forming polymers are positively charged at physiological conditions. 25. The method of claim 24 , wherein the anionic surfactant is selected from the group consisting of sodium dodecyl sulfate, sodium stearate, and charged fatty acid surfactan

Assignees

Inventors

Classifications

  • Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

  • A61K9/06Primary

    Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

  • Cellulose; Derivatives thereof · CPC title

  • Polyesters, e.g. poly(lactide-co-glycolide) · CPC title

  • obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11517538B2 cover?
Network materials which exhibit both shear thinning and self-healing properties are disclosed. The networks contain particles and gel-forming compounds. The networks are useful for a variety of biomedical uses, including drug delivery.
Who is the assignee on this patent?
Massachusetts Inst Technology
What technology area does this patent fall under?
Primary CPC classification A61K9/06. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).